The functional role of glucocorticoid-mediated GR signaling has been more extensively investigated in the growth of hematological malignancies, as well as that of solid endocrine tumors, such as breast and prostate cancers, relating to its interplay with ER and AR, respectively. This evidence concerns the gene NR3C1 and prostate carcinoma.